Bio-Techne Corporation (TECH)

Life science reagents and instruments maker. Read November 9, 2026 from the annual report for the period ending June 30, 2026, filed August 24, 2026. Ranked 81 of the 145 Healthcare companies read so far, by the share within reach now.

The filing states approximately 3,000 full-time and part-time employees at June 30, 2026, 2,200 in the U.S., with consumables 88% of revenue, so the reagent and assay production leads at pharmaceutical and medicine manufacturing and the instruments take the instruments group by description.

The figures on this page come from the company's own annual report and from BLS staffing patterns for its industries, never from a roster. They are estimates with a stated method. Nothing here says what the company will do: within reach is not a forecast of jobs lost or of savings.

What follows from the reading

Share of working time within reach of AI, on the long-run pace at four in five: 32% now, 42% at the end of 2027, 45% at the end of 2028, 46% at the end of 2030. By the patterns, the work is about 46% desk work, 14% people work and 40% body work. These are the site's industry estimates weighted by the shares below: estimates with a stated method and range, not a forecast of what the company will do. By the same patterns, at the end of 2028 about 55% of the working time stays with people (conversation, in-person and hands-on work), 39% becomes checking a model's work and 4% could be handed over with lighter checks, from the industries' own figures, not the company's roles.

Headcount

3,000 employees as of June 30, 2026 (stated). Approximately 2,200 of 3,000 employees in the U.S. and 800 outside (stated).

The filing: “Through its subsidiaries, Bio-Techne employed approximately 3,000 full-time and part-time employees as of June 30, 2026, of whom approximately 2,200 were employed in the U.S. and approximately 800 outside the U.S.”

The workforce as industry patterns

What the filing says about the workforce: Approximately 3,000 full-time and part-time employees at June 30, 2026, about 2,200 in the U.S. and 800 outside; none of the U.S. employees are unionized, with government-mandated collective bargaining or works councils in certain countries; three-fourths took the fiscal 2026 engagement survey; 11 employee resource groups.

Companies read with the same leading pattern

Other companies whose largest staffing pattern is also Pharmaceutical and Medicine Manufacturing, largest first, each read from its own annual report. Within reach now and at the end of 2028, long-run pace, four in five. Now is projected from METR's April 2026 measurement and Epoch's November 2026 index.

• Johnson & Johnson (JNJ, 140,800 employees)30% now, 41% by 2028
• Thermo Fisher Scientific Inc. (TMO, 125,000 employees)36% now, 53% by 2028
• Merck & Co., Inc. (MRK, 75,000 employees)32% now, 44% by 2028
• Pfizer Inc. (PFE, 75,000 employees)32% now, 44% by 2028
• AbbVie Inc. (ABBV, 57,000 employees)32% now, 44% by 2028
• Eli Lilly and Company (LLY, 50,000 employees)32% now, 44% by 2028
• Bristol-Myers Squibb Company (BMY, 32,500 employees)32% now, 44% by 2028
• Amgen Inc. (AMGN, 31,500 employees)32% now, 44% by 2028

What the filing says about AI

0 sentences in the filing name AI. The filing names artificial intelligence in no sentence.

Its annual reports, year by year

Sentences naming AI in each annual report, counted by one rule, beside the median report in the Index that year. Each count links its filing. Every company, by year and sector

• Fiscal 20210median 0
• Fiscal 20220median 0
• Fiscal 20230median 1
• Fiscal 20240median 4
• Fiscal 20250median 10
• Fiscal 20260

Headcount by filing year

As reported in each year's annual report, with the filing. A year marked not read had no figure the reading could take from the report's text.

Limits of this reading

• The filing counts nothing by segment, so the split between consumables and instruments follows the revenue lines by description (c).

Source: the company's annual report on EDGAR, accession 0001104659-26-100322, the filing. Read by Claude Fable 5.1 under rubric version 1, by the method. A company can write to info@stratussc.com to have its reading checked against its filing.